Cyclin-dependent kinase (CDK) 4/6 inhibitors show great results in various clinical trials and also have improved the medical outcome for individuals with hormone-receptor-positive, human being epidermal growth factor receptor 2-negative advanced breast cancer significantly. extra authorization in the neo-/adjuvant establishing. letrozole only10.2 20.2 months PFSPALOMA-2 [NCT01942135]4Postmenopausal, HR+/HER2? ABC36661st linePalbociclib* + letrozole letrozole only24.8 14.5 months… Continue reading Cyclin-dependent kinase (CDK) 4/6 inhibitors show great results in various clinical